Article

Clinicopathological characteristics of rectal carcinoids

Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, 388-1 Poongnap-dong, Songpa-gu, Seoul 138-736, Republic of Korea.
International Journal of Colorectal Disease (Impact Factor: 2.42). 09/2010; 25(9):1087-92. DOI: 10.1007/s00384-010-0949-y
Source: PubMed

ABSTRACT Carcinoids are heterogeneous neuroendocrine tumors with malignant potential. The rectum is the third most common location for gastrointestinal carcinoids. We assessed the clinicopathological characteristics of rectal carcinoids.
A retrospective study of 203 patients treated for rectal carcinoids at the Asan Medical Center, Seoul, Republic of Korea from 1991 to 2007.
The patients were on average 51 (18-83) years old. The male-to-female ratio was 1.48:1. Over half (62.1%) of the patients were asymptomatic. The most frequent symptoms in the symptomatic patients were abdominal pain (11.1%) and hematochezia (10.7%). Local excision was applied to 92.1%, low anterior resection to 4.9%, and biopsy only to 3.0% of total patients. Initially, 4.4% presented with distant metastasis. Distant metastasis rates for tumors < or =1 cm, >1 to < or =2 cm, and >2 cm were 1.7% (3/177), 15.0% (3/20), and 50.0% (3/6), respectively. In the follow-up period, three patients showed recurrences. The size, lymphovascular invasion, perineural invasion, and T and N stages were associated with distant metastasis. The overall 5-year survival rate was 94.0%. The TNM stage and presence of lymphovascular invasion were associated with lower survival.
The chance that a rectal carcinoid will develop distant metastases increases as the tumor increases in size, lymphovascular invasion or perineural invasion is present, and T and N stages increase. The TNM stage and presence of lymphovascular invasion were associated with lower survival. Treatment plan should be chosen carefully considering above factors.

0 Followers
 · 
101 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The incidence of colorectal neuroendocrine tumors (NETs) is rising in developed countries primarily as a result of increased incidental detection by endoscopy and probably also due to a more adequate diagnosis according to the WHO classification. Less than 1% of colorectal NETs produce serotonin so that such tumors are practically never associated with a hormonal carcinoid syndrome. An exact clinico-pathological staging is of paramount importance for the therapeutic strategy and comprises the classification of the tumor type (well or poorly differentiated) and the assessment of established prognostic risk factors (depth of infiltration, vascular invasion, lymph node and distant metastases). Poorly differentiated colorectal NETs often present in an advanced, metastatic state, where surgical therapy is basically palliative. Well-differentiated tumors larger than 2 cm have a high risk of metastatic spread and should be treated as adenocarcinomas by radical oncological surgical resection. This applies to the majority of colon NETs. Tumors smaller than 1 cm, mainly locacted in the rectum, only rarely metastasize and are usually accessible for endoscopic treatment or transanal local surgery. Tumors between 1 and 2 cm in size have an uncertain prognosis and additional risk factors and co-morbidities of the patient have to be considered for a suitable, multidisciplinary therapeutic decision.
    Der Chirurg 06/2011; 82(7):607-11. · 0.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Inzidenz der kolorektalen neuroendokrinen Tumoren (NETs) ist in den letzten Jahrzehnten in den entwickelten Ländern deutlich angestiegen. Dies ist in erster Linie der zunehmenden Verbreitung der (Vorsorge-)Endoskopie geschuldet, die immer häufiger klinisch asymptomatische Tumoren entdeckt, möglicherweise aber auch einer häufigeren Diagnosestellung entsprechend der WHO-Klassifikation. Weniger als 1% der kolorektalen NETs produzieren Serotonin, sodass diese Tumoren fast nie mit einem „Karzinoidsyndrom“ auffallen. Zur Festlegung der adäquaten Therapiestrategie ist ein exaktes und standardisiertes klinisch-pathologisches Staging unerlässlich, das den Tumortyp (gut – schlecht differenziert) und prognostische Risikofaktoren (Größe, Infiltrationstiefe, Angioinvasion, Lymphknotenbefall, Fernmetastasierung) umfasst. Schlecht differenzierte kolorektale NETs sind bei Diagnosestellung häufig bereits metastasiert, sodass der chirurgischen Therapie häufig nur eine palliative Rolle zukommt. Gut differenzierte Tumoren von mehr als 2cm Größe haben ein hohes Risiko für eine (Lymphknoten-)Metastasierung; sie werden dementsprechend onkologisch radikal wie Adenokarzinome operiert. Die Mehrzahl der Kolon-NETs fällt in diese Gruppe. Tumoren kleiner 1cm – hauptsächlich im Rektum lokalisiert – metastasieren sehr selten und können in der Regel endoskopisch oder transanal lokal-chirurgisch abgetragen werden. Der Größenbereich zwischen 1 und 2cm stellt eine prognostische Grauzone dar: Hier muss unter Berücksichtigung der tumorspezifischen Risikofaktoren und der Komorbiditäten des Patienten eine individuelle und am besten gemeinsame interdisziplinäre Therapieentscheidung von Chirurg und Endoskopiker getroffen werden. The incidence of colorectal neuroendocrine tumors (NETs) is rising in developed countries primarily as a result of increased incidental detection by endoscopy and probably also due to a more adequate diagnosis according to the WHO classification. Less than 1% of colorectal NETs produce serotonin so that such tumors are practically never associated with a hormonal carcinoid syndrome. An exact clinico-pathological staging is of paramount importance for the therapeutic strategy and comprises the classification of the tumor type (well or poorly differentiated) and the assessment of established prognostic risk factors (depth of infiltration, vascular invasion, lymph node and distant metastases). Poorly differentiated colorectal NETs often present in an advanced, metastatic state, where surgical therapy is basically palliative. Well-differentiated tumors larger than 2cm have a high risk of metastatic spread and should be treated as adenocarcinomas by radical oncological surgical resection. This applies to the majority of colon NETs. Tumors smaller than 1cm, mainly locacted in the rectum, only rarely metastasize and are usually accessible for endoscopic treatment or transanal local surgery. Tumors between 1 and 2cm in size have an uncertain prognosis and additional risk factors and co-morbidities of the patient have to be considered for a suitable, multidisciplinary therapeutic decision. SchlüsselwörterNeuroendokrine Tumoren–Kolon–Rektum–Chirurgische Resektion–Endoskopie KeywordsNeuroendocrine tumors–Colon–Rectum–Resection–Endoscopy
    Der Chirurg 07/2011; 82(7):607-611. DOI:10.1007/s00104-011-2072-1 · 0.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neuroendocrine tumors (NETs) are found throughout the intestinal tract and arise from the Kulchitsky cells located in the crypts of Lieberkühn. They are classified by site of origin and by degree of differentiation, with well-differentiated lesions representing those tumors formerly referred to as carcinoid tumors. The focus of this review is NETs of the appendix, colon, and rectum. The clinical presentation of these tumors is dependent on the primary site and many are discovered incidentally, either during screening or during the investigation of nonspecific abdominal complaints. Treatment is primarily via surgical removal as the response to chemotherapy has been traditionally poor. A noted exception to this has been with treatment of the carcinoid syndrome, which occurs almost exclusively in patients with liver metastases and is due to the release of bioactive peptides and amines directly into the systemic circulation. The use of somatostatin congeners to block the release of these substances has greatly ameliorated the devastating symptoms of this condition. Postresection follow-up is advocated, but specific recommendations are lacking an evidentiary basis. NETS, particularly those of the small bowel, colon, and appendix, are seen in association with other synchronous or metachronous malignancies, often of the gastrointestinal tract. However, the utility of subsequent screening and surveillance is unproven.
    09/2011; 24(3):129-34. DOI:10.1055/s-0031-1285996
Show more